



Glycine receptor mutants of the mouse: what are possible routes of inhibitory compensation?

Natascha Schaefer^{1,2}, Nicolas Vogel¹ and Carmen Villmann^{2*}

¹ Emil Fischer Center, Institute of Biochemistry, University Erlangen-Nuernberg, Erlangen, Germany

² Institute for Clinical Neurobiology, University of Wuerzburg, Wuerzburg, Germany

Edited by:

Piotr Bregestovski, Institut de Bioenginyeria de Catalunya, Spain

Reviewed by:

Pascal Legendre, Université Pierre et Marie Curie CNRS INSERM, France

Stéphane Supplisson, Ecole Normale Supérieure, France

*Correspondence:

Carmen Villmann, Institute for Clinical Neurobiology, University of Wuerzburg, Versbacherstr. 5, D-97078 Wuerzburg, Germany.
e-mail: villmann_c@klinik.uni-wuerzburg.de

Defects in glycinergic inhibition result in a complex neuromotor disorder in humans known as hyperekplexia (OMIM 149400) with similar phenotypes in rodents characterized by an exaggerated startle reflex and hypertonia. Analogous to genetic defects in humans single point mutations, microdeletions, or insertions in the *Gla1* gene but also in the *GlrB* gene underlie the pathology in mice. The mutations either localized in the α (*spasmodic*, *oscillator*, *cincinnati*, *Nmf11*) or the β (*spastic*) subunit of the glycine receptor (GlyR) are much less tolerated in mice than in humans, leaving the question for the existence of different regulatory elements of the pathomechanisms in humans and rodents. In addition to the spontaneous mutations, new insights into understanding of the regulatory pathways in hyperekplexia or glycine encephalopathy arose from the constantly increasing number of knock-out as well as knock-in mutants of GlyRs. Over the last five years, various efforts using *in vivo* whole cell recordings provided a detailed analysis of the kinetic parameters underlying glycinergic dysfunction. Presynaptic compensation as well as postsynaptic compensatory mechanisms in these mice by other GlyR subunits or GABA_A receptors, and the role of extra-synaptic GlyRs is still a matter of debate. A recent study on the mouse mutant *oscillator* displayed a novel aspect for compensation of functionality by complementation of receptor domains that fold independently. This review focuses on defects in glycinergic neurotransmission in mice discussed with the background of human *hyperekplexia en route* to strategies of compensation.

Keywords: GlyRs, synaptic inhibition, spontaneous mouse mutants, knockout mice, hyperekplexia, rescue

INTRODUCTION

Synaptic inhibition is mediated by activation of glycine receptors (GlyRs) and γ -aminobutyric acid (GABA) receptors. GlyRs mediate fast inhibitory neurotransmission in the adult spinal cord, which is important for motor control. Functional impairments of spinal GlyRs or associated proteins lead to the rare neuromotor disorder hyperekplexia (Startle disease, Stiff Baby Syndrome, OMIM #149400) in humans with similar phenotypes in rodents. In hyperekplexia, affected neonates exhibit exaggerated startle responses and muscle stiffness following an unexpected acoustic noise or a tactile stimulus, which may result in fatal apnea. During early childhood the muscle tone returns to normal levels, but startle persists into the adulthood (Andermann et al., 1980; Shiang et al., 1993; Becker et al., 2008). Predominantly, single point mutations in the *GLRA1* gene encoding the GlyR subunit $\alpha 1$ (GlyR $\alpha 1$) underlie the pathology in humans. Analogous genetic defects have been observed in mice. The mutations are either localized in the α (*spasmodic*, *oscillator*, *cincinnati*, *Nmf11*) or the β (*spastic*) subunit of the GlyR. Recently, other animal models of glycinergic dysfunction have been reported in zebrafish (*bandoneon*, *shocked*) and cow (*CMD2*). Among the mouse mutations, *spasmodic*, *spastic*, *oscillator*, and *cincinnati* harbor spontaneous mutations, the *Nmf11* mouse mutant instead results from chemical induction (Buckwalter et al., 1994; Kingsmore et al., 1994; Mulhardt et al., 1994; Ryan et al., 1994; Holland

et al., 2006; Traka et al., 2006). These mouse models of GlyR dysfunction have served as excellent systems for studying the pathomechanisms of the corresponding human neurological disease. It turned out, however, that the phenotype in mice is much more severe than in humans, e.g., a functional null allele is lethal in mice (*oscillator*) but not in humans, arguing for different compensatory mechanisms in both organisms (Tsai et al., 2004; Becker et al., 2006). The response to clonazepam treatment is another example for differences in compensatory effects. In patients, startle attacks are reduced and a normal muscle tone could be reached following clonazepam treatment. The benzodiazepine clonazepam enhances GABA-gated chloride currents upon binding to GABA_A receptors exhibiting an up-regulation of GABAergic neurotransmission as one possible compensatory mechanism at least in humans. In contrast, no similar mechanism seems to exist in mice after clonazepam treatment. Here, background effects as well as the existence of other so far unidentified regulatory proteins or modulators of the disease are under discussion (Buckwalter et al., 1994; Becker et al., 2006; Molon et al., 2006). In the two mouse models *spastic* and *oscillator* a functional rescue has been shown using different approaches *in vitro* and *in vivo*. With a transgenic approach in the mouse mutant *spastic* the phenotype was rescued by restoring the β expression levels toward sufficient amounts for proper functioning of glycinergic synapses (Hartenstein et al., 1996). Using a

complementation strategy, $\alpha 1$ levels came up in spinal cord neurons isolated from homozygous *oscillator* mice (Villmann et al., 2009a).

This review will discuss the various mouse models of glycinergic disinhibition to understand the pathomechanisms and regulatory pathways of the neuromotor disorder hyperekplexia. With the help of knock-out, and knock-in studies of GlyR subunits, including novel strategies such as rescue experiments new perspectives of pre- or postsynaptic compensation will be elaborated.

GLYCINERGIC SYNAPSES AND NEUROMOTOR BEHAVIOR

Glycinergic neurons appear during development in the vertebrate central nervous system (CNS) from embryonic day 12.5 (E12.5) on in the somata of ventral horn cells in the spinal cord, followed by cells in the dorsal horn one day later (Allain et al., 2006; Chalphin and Saha, 2010). Prominent GlyR immunoreactivity has been also detected in the ventral and dorsal horns of the spinal cord, the spinal trigeminal nuclear complex, the dorsal motor nucleus of the vagus nerve, and the hypoglossal nucleus (Rampon et al., 1996; Baer et al., 2009). Further GlyR expression in the adult CNS has been determined in midbrain, caudal and rostral pons, rostral medulla oblongata, retina, different nuclei of the forebrain, and the cochlea (Greferath et al., 1994; Baer et al., 2003; Waldvogel et al., 2007; Długańczyk et al., 2008).


In early stages of development GABAergic transmission predominates over glycinergic transmission. At this time both neurotransmitters depolarize neurons (Gonzalez-Forero and Alvarez, 2005; Scaini et al., 2010). In the neonatal brain many inhibitory synapses initially are mixed GABAergic and glycinergic, which changes during CNS maturation between P5 and P14 depending on the CNS area (Jonas et al., 1998; Kotak et al., 1998). The switch toward glycinergic transmission has been observed in many spinal and brainstem synapses, e.g., in the lumbar spinal cord and in the lateral superior olive of young rodents (Gao et al., 2001; Nabekura et al., 2004; Muller et al., 2006; Scaini et al., 2010). But there are also regions in which GABAergic neurotransmission dominates in the developing brain for example in the collicular neurons (Meier et al., 2002).

Important in the maturation of ventral inhibitory synapses are the developing interneurons (e.g., IaIN, V2b, Renshaw cells), which possess diverse roles in shaping locomotor patterns. These interneurons are assigned to enable reciprocal (Ia inhibitory neurons), feedback (Renshaw cells), and feed-forward (presynaptic sensory) inhibition (**Figure 1**) (Siembab et al., 2010). Compared to other ventral interneurons, Renshaw cells become greatly potentiated inhibitory synaptic inputs during postnatal development as a consequence of functional adaptation. Renshaw cell-mediated recurrent inhibition allows the control of the dynamic behavior of motoneuron (MN) firing (Gonzalez-Forero and Alvarez, 2005; Alvarez and Fyffe, 2007). Neuromotor behavior is fine-tuned by recurrent inhibition, which involves the action of GlyRs binding the inhibitory neurotransmitter glycine. The activation of GlyRs leads to chloride influx and therefore hyperpolarization of the motoneuronal membrane restoring the balance between excitation and inhibition (**Figure 1**). This feedback circuit emphasizes the importance of glycinergic inhibition in the adult spinal cord and brainstem.

Disturbances in GlyR inhibition due to a single amino acid substitution in one of the GlyR subunits give rise to a different MN-firing pattern associated with overactivation of the muscle and muscle stiffness. Such symptoms are observed in patients suffering from hyperekplexia. These patients carry a mutant allele with either a single nucleotide polymorphism (SNP) leading to an amino acid exchange at the protein level, deletions of various exons or nonsense mutations (Harvey et al., 2008). Dominant mutations have been shown to result in differences in physiological properties of the ion channel itself. The majority is localized within the ion channel domain itself and adjacent loop structures (Lynch et al., 1997). Recessive mutations showed up with a disturbed biogenesis with regard to trafficking and accumulation in the endoplasmic reticulum. In addition, the stability of these mutants is highly affected (Villmann et al., 2009b). In homozygous mutant mice point mutations within the *Gla1* and the *GlrB* gene result in similar phenotypes with typical startle attacks, massive tremor and rigidity from postnatal day 15 on. This has been shown for spontaneous mouse mutants as well as for knock-in animals carrying point mutations that were identified in human patients (Findlay et al., 2003; Borghese et al., 2012). Between postnatal days 15 and 21 the disease is highly progressive and lethal for the majority of mutants. The lethal phenotype has been noted for mutations in the $\alpha 1$ and β subunit, both of which are part of the adult receptor complex. In contrast, $\alpha 2$ or $\alpha 3$ knockout animals do show a rather mild phenotype (Harvey et al., 2004; Young-Pearse et al., 2006). Thus, compensatory mechanisms get rather initialized by a complete loss of protein function than following the expression of misfolded receptor proteins accumulating in the cell, respectively.

GLYCINE RECEPTORS—LIGAND-GATED CHLORIDE CHANNELS

GlyRs are members of the superfamily of Cys-loop receptors (CLRs) as the nicotinic acetylcholine receptors, the 5HT₃ receptor, and GABA_{A/C} receptors (Lynch, 2009). The overall topology of a single subunit with a conserved disulphide bridge in the N-terminus is common to all members of the CLR family (Lynch, 2004). Characteristic features are a short C-terminus and a highly structured N-terminus, which exhibits a high homology to the acetylcholine binding protein of the pond snail *Lymnaea stagnalis*, whose structure was solved by X-ray crystallography with a resolution of 2.7 Å (Brejc et al., 2001). The N-terminal domain displays an immunoglobulin-like structure characterized by a short α -helical domain in the far N-terminus followed by 10 β -sheets. Meanwhile, the X-ray structure of other members of the CLR superfamily has been solved, e.g., GLIC and ELIC (Hilf and Dutzler, 2008, 2009; Bocquet et al., 2009), two members of prokaryotic origin, and the GluCl, a glutamate-gated chloride channel from *C. elegans* with 34% protein identity to the GlyR structure (Hibbs and Gouaux, 2011). Furthermore, each subunit comprises 4 transmembrane domains (TMs) connected by intra- or extracellular loop structures. TM2 forms the ion channel pore. The highest diversity among GlyR subunits and also among different families of CLRs lies in the large TM3-4 loop. This loop is thought to be important for biogenesis and



posttranslational modifications (Sadler et al., 2003; Breiting et al., 2009; Villmann et al., 2009a).

Upon agonist binding toward the ligand-binding cavity (Brejč et al., 2001; Unwin, 2005) an intrinsic chloride channel opens. The structural data have shown that amino acids from N-terminal loop structures, loops A, B, and C from one subunit (plus side or principal face) together with loops D, E, and F from another subunit (minus side or complementary face) form the ligand binding cavity between different subunits. The adult receptor channel complex consists of 5 subunits assembling into a rosette-like heteropentamer of two α and three β subunits both of which are involved in ligand binding (Grudzinska et al., 2005; Dutertre et al., 2012). The opening of the GlyR ion channel pore follows a ligand-induced (starting with the highest affinity: glycine > β -alanine > taurine) transition process (Lynch, 2004).

GlyR SUBUNIT DIVERSITY AND DEVELOPMENTAL REGULATION

At present four GlyR α -subunits encoded by different genes are known, as well as one single β -subunit. Alternative splicing of the α subunits as well as the β -subunit results in further diversity of GlyR complexes (Malosio et al., 1991a; Kuhse et al., 1993; Nikolic et al., 1998; Harvey et al., 2004; Heinze et al., 2007; Oertel et al., 2007).

GlyR α 1 exists in two splice variants (α 1ins described for rat, mice, and humans) with one harboring additional 8 amino acids in the TM3-4 loop (Malosio et al., 1991a; Strausberg et al., 2002). Both α 1 variants do not differ in physiological characteristics in transfected cell lines. The α 1 subunit mRNA in rats is first detectable at postnatal day 5 and increases constantly into the adulthood (Malosio et al., 1991b; Sato et al., 1991). The expression of the α 1 is most prominent in brain nuclei and spinal cord; some immunoreactivity was observed in the superior and inferior folliculi and regions of the hypothalamus and in the thalamus (Sato et al., 1991). The mRNA of α 2 has been detected first around embryonic day E15 and decreased after birth (Malosio et al., 1991b). Originally, a developmental switch from a neonatal isoform GlyR $_N$ composed of α 2 homomers to the adult isoform (GlyR $_A$) α 1 β heteromers was postulated. This switch was proposed to be complete by postnatal day 20. For GlyR α 2 also two alternative splice variants with alternative exons 3 have been described, either exon 3A or 3B. The resulting proteins differ in only two amino acid residues in the extracellular N-terminal part of the receptor (Kuhse et al., 1991). Recent findings suggest that the α 2 expression persists into adulthood in retina, cerebellum, and auditory brain stem (Piechotta et al., 2001; Young and Cepko, 2004; Heinze et al., 2007; Nobles et al., 2012). GlyR α 3 also exists in two splice variants, differing in a 15 amino acid insertion in the TM3-4 loop (α 3L and α 3K). Both variants

show similar distribution which is comparable to the $\alpha 1$ subunit, but with significantly less intensity. In contrast to the $\alpha 1$ splice isoforms $\alpha 3L$ and $\alpha 3K$ differ in ion channel properties, e.g., in desensitization behavior with $\alpha 3K$ forming fast desensitizing channels and $\alpha 3L$ representing the slower desensitizing receptor complexes (Nikolic et al., 1998). In addition, RNA editing has been shown to increase the diversity of GlyR $\alpha 3$ (Meier et al., 2005). The $\alpha 3$ variant P185L emerges from cytidine 554 deamination (C554U). Neurons harboring $\alpha 3P185L$ assign high glycine potency and non-desensitized receptors, which are prerequisites for tonic inhibition (Stell and Mody, 2002). The $\alpha 4$ subunit has been found in the adult mouse retina where it clusters together with synaptic markers such as bassoon or gephyrin (Heinze et al., 2007). Furthermore, GlyR $\alpha 4$ transcripts have been detected in the white matter tract of the developing spinal cord from mice. The avian $\alpha 4$ mRNA was also found in dorsal root ganglia and genital ridge. Although the function of GlyR $\alpha 4$ at its sites of expression is still unknown, homomeric $\alpha 4$ receptors are able to form fully functional glycine-gated Cl⁻ channels *in vitro* that can be antagonized with strychnine (Harvey et al., 2000).

GlyR β transcripts are widely expressed also in organs where no α subunit is present. The β expression starts around E14 but increases rapidly after birth (Malosio et al., 1991b). The β subunit is part of the adult GlyR complex, which is composed of 2 α and 3 β subunits (Grudzinska et al., 2005) with $\alpha 1\beta$ representing the major form of heteromers. The function of the β subunits in tissues lacking GlyR α subunits is still enigmatic. Synaptic GlyRs are clustered by gephyrin via an interaction motif in the TM3-4 loop of the β subunits. Gephyrin is a scaffolding protein in the plasma membrane that mediates mobility of GlyRs and thereby contributes to the plasticity of inhibitory synapses (Fritschy et al., 2008; Calamai et al., 2009).

SPONTANEOUS MOUSE MUTANTS OF THE *Glr1* AND *Glr2* GENE

To date five spontaneous and recessively inherited mutations in mice serve as models for human *hyperekplexia*. Four mutations occurred without any manipulation, such as *spasmodic* (*spd*), *oscillator* (*spd^{ot}*), *cincinnati*, and *spastic* (*spa*) (Figure 2, Table 1). The fifth spontaneous mutation *nmf11* was induced by ENU (N-ethyl-N-nitrosourea), which is a powerful chemical mutagen that offers the possibility to induce point mutations genome-wide with a high frequency (Balling, 2001). This part will discuss the spontaneous mutations with regard to symptoms and progression of the disease, the genetic location of the mutations, and the resulting failure at the protein level being responsible for the phenotype of affected mice.

THE SPASMODIC MOUSE MUTANT—A MISSENSE MUTATION

Homozygous *spd/spd* mice develop hyperekplexia like phenotypes characterized by an exaggerated acoustic startle reflex, high tremor, and an impaired righting reflex. Symptoms start in the third week after birth. Before this period, *spd/spd* mice are phenotypically normal and are indistinguishable from heterozygous or wild type siblings. No progression within the symptoms can be observed with age and homozygous mutants do have a normal life expectancy (Lane et al., 1987).




FIGURE 2 | Overview about GlyR mouse mutants from DNA level to the protein level. The *Glr1* gene comprises 9 exons (*Glr2* 10 exons). Left column: SNPs are indicated by numbers. The C to T transition at position 159 in *spasmodic* mice is shown. The microdeletion in exon 8 of the *oscillator* mouse is listed by an insertion. In addition, exon 9 harbors an alternative splicing cassette (ASC) responsible for the generation of the two different mRNAs in the adult organism. For the *cincinnati* mouse the intronic internal repeats (GGGGC) responsible for exon 5 duplication are shown. In the *Nmf* mutant a C to A transition in exon 2 of the *Glr1* gene was demonstrated. The insertion of the LINE1 element into intron 6 of the *Glr2* gene is marked. Aberrant splicing is indicated by dotted lines. Middle column: represents the different mRNAs, which are formed. SNPs are marked with numbers below the appropriate exon, e.g., *spd* C159T. Two mRNAs are generated in *oscillator* due to alternative use of the splice acceptor site in exon 9. Usage of this site leads to exclusion of the ASC (24 bp), non-usage generates an mRNA with the 24 bp ASC. *Cincinnati* harbors the exon 5 duplication with generation of a premature stop codon. The SNP C138A in the *Nmf11* mouse is marked. As a consequence of the LINE1 insertion into intron 6 of the *Glr2* gene, aberrant splicing with exon 6 and exon 5/6 exclusion are observed. Right column refers to the GlyR proteins. In *spasmodic* mice a GlyR harboring the A52S mutation decreasing glycine affinity is marked. The premature STOP codons in *oscillator* and *cincinnati* result in no expression of GlyR $\alpha 1$. The single amino acid exchange N46K in the *Nmf* mutant is due to the C to A transition in exon 2 of the *Glr1* gene. Aberrant splicing of *Glr2* in the *spastic* mouse model results in a highly reduced number of full-length GlyR β .

A point mutation in the *Glr1* gene at chromosome 11, which leads to a change of an alanine into a serine at position 52 of the mature polypeptide sequence, has been found as the genetic reason for the phenotype in *spasmodic* mice (Ryan et al., 1994). The *spd* locus on chromosome 11 is linked by

Table 1 | Spontaneous and induced GlyR mouse mutants.

Mouse mutant	Gene	Chromosome	DNA level	Protein level	Physiological effect	Lifespan	Further characteristics	References
<i>Spasmodic</i> (spontaneous)	<i>Gira1</i>	11	G159T (exon 3)	A52S*	Decrease in glycine binding affinity	Normal symptoms start in third postnatal week	-	Ryan et al., 1994; Saul et al., 1994
<i>Oscillator</i> (spontaneous)	<i>Gira1</i>	11	Microdeletion of 9bp and microinsertion of 2 bp (exon 8)	P327X*	Loss of function (NULL mutation), no synaptic localization	Lethal about three weeks symptoms start in second postnatal week	Rescue of GlyR α 1 function has been shown <i>in vitro</i>	Buckwalter et al., 1994; Kling et al., 1997; Villmann et al., 2009a
<i>Cincinnati</i> (spontaneous)	<i>Gira1</i>	11	Duplication of exon 5	F159X*	Loss of function (NULL mutation), no synaptic localization	Lethal about three weeks symptoms start in second postnatal week	-	Holland et al., 2006
<i>Nmf11</i> (induced)	<i>Gira1</i>	11	C138A (exon 3)	N46K*	no physiological data synaptic localization	Lethal about three weeks	ENU induced	Traka et al., 2006
<i>Spastic</i> (spontaneous)	<i>Gltb</i>	3	Insertion of LINE 1 element (intron 6)	less full-length GlyR β	Deficient mRNA splicing with functional β mRNA levels being decreased to approximately 10%	Lethal about three weeks symptoms start in the second postnatal week	Backcross strain F1(C57BL/6J \times C3H/HeJ) \times C57BL/6J (C3H) show milder symptoms and mostly survive the critical age	Kingsmore et al., 1994; Mulhardt et al., 1994; Becker et al., 2012


*Amino acid positions refer to the mature protein.

synteny homology to the human chromosomal region 5q21–q31, where the $\alpha 1$ subunit gene has been mapped (Shiang et al., 1993). A further but silent mutation was found at position 198 (Figure 2, Table 1) (Matzenbach et al., 1994; Saul et al., 1994). Although these animals develop a phenotype, the location of the protein seems not to be affected. The X-ray structure solved from homologous CLR protein AchBP defined various loop structures within the N-terminal domain of the protein that are involved in ligand binding (Brejc et al., 2001). The amino acid position A52S does not lie within this interface between two adjacent subunits, neither at the plus nor at the minus site of ligand binding. A52S only flanks the proposed assembly boxes and seems not to impair the overall protein content of GlyR $\alpha 1$ which is indistinguishable between wild type and homozygous *spasmodic* mice (Saul et al., 1994). In these channels the binding affinity of the agonists glycine, β -alanine and taurine is altered with a rightward shift in the glycine EC₅₀ (Figure 3) (Saul et al., 1994; Graham et al., 2006, 2011). Excised

patches from spasmodic superficial dorsal horn (SFDH) neurons show no single channel openings at low glycine concentration and only a few openings to high glycine concentrations compared to wild type neurons with multiple channel openings at the same glycine concentration. A detailed characterization of another point mutation at position 52 (A52C) within $\beta 1$ – $\beta 2$ loop suggests that the microenvironment of A52 is responsible for different conformations of the $\beta 1$ – $\beta 2$ loop and thereby hamper the agonist glycine from binding to the subunit interface (Pless and Lynch, 2009).

THE OSCILLATOR MOUSE—A FRAMESHIFT MUTATION LEADING TO COMPLETE LOSS OF FUNCTION

Homozygous *oscillator* mice represent a null mutation accompanied by a lethal phenotype. In contrast to *spasmodic* mice, *oscillator* mice always die within 3 weeks of age. Their neuromuscular symptoms like fine tremor and muscle spasm start at the age of 2 weeks and worsen progressively. The symptoms of



this phenotype are highly comparable to strychnine poisoning in humans.

The genetic cause is also a mutation in the *Gla1* gene (Buckwalter et al., 1994). The *oscillator* allele *Gla1^{spd-ot}* exhibits a microdeletion of 9 bp plus a microinsertion of 2 bp resulting in a frameshift. Depending on differential use of two splice acceptor sites in exon 9 of *Gla1* (Figure 2, Table 1), two $\alpha 1$ polypeptide mutants are encoded, both of which lack TM4 (Malosio et al., 1991a). Inclusion of the alternative splice cassette resulted in a premature STOP codon within this 8 amino acid cassette thereby comprising a truncated $\alpha 1$ variant (*spd^{ot}-trc*). The long splice variant, *spd^{ot}-elg*, was generated from an exclusion of the alternative 24 bp and encodes 150 missense residues at the C-terminus (Villmann et al., 2009a).

Due to the frameshift motifs important for receptor biogenesis and trafficking are destroyed (Sadtler et al., 2003). In the CNS of homozygous *oscillator* mutants, a complete loss of functional GlyR $\alpha 1$ protein neither *spd^{ot}-trc* nor *spd^{ot}-elg* was observed, characterizing *oscillator* as a functional null mutation of the *Gla1* gene (Kling et al., 1997). Using an independent domain approach *in vitro*, we were able to show that the truncated GlyR $\alpha 1$ subunit variant *spd^{ot}-trc* can efficiently be rescued by coexpression with an independent C-terminal tail domain representing the lacking GlyR $\alpha 1$ protein proportion (most of the TM3-4 loop, TM4, and the C-terminus). This functional complementation of GlyRs demonstrated the importance of the TM3-4 loop for biogenesis, clustering and pharmacological properties as demonstrated in transfected HEK293 cells and spinal cord neurons from *ot/ot* animals (Figure 4). Such reconstruction of a functional ligand-gated ion channel by independent folding domains resembles novel directions for compensatory mechanisms using gene therapeutic approaches (Villmann et al., 2009a). *In vivo* recordings in hypoglossal MNs of homozygous *oscillator* mice demonstrated a dramatic decrease in frequency and amplitude of mIPSCs together with a much slower decay time compared to heterozygous control mice. The fact of any glycinergic mIPSCs in the functionally null mutant *ot/ot* suggests a compensation via $\alpha 2$, $\alpha 3$, or $\alpha 4$ subunits expressed in MNs; however, these at distal dendritic locations expressed receptor clusters are not sufficient to sustain life (Graham et al., 2006).

THE CINCINNATI MOUSE—ANOTHER FRAMESHIFT MUTATION

Cincinnati is a spontaneous mutation in the *Gla1* gene with a similar phenotype to the other spontaneous mouse mutants already described. At 2 weeks of age, affected mice exhibit impaired righting reflex and tremor. This progress worsens till their death within 3 weeks of age as observed for *oscillator* mice (Figure 2, Table 1) (Holland et al., 2006). The mutant was recognized by the generation of multiple affected offsprings from one mating. Further breedings with obligate heterozygote animals with the strain C3H/HeCr1BR showed more mutants among the F1 generation. Further random crosses with the mentioned strain showed a recessively inherited autosomal inheritance.

Analysis of the genomic sequence did not show any insertions of LINE or SINE (long or short interspersed nuclear elements) elements as seen in *spastic*. But in introns 4 and 5 of *Gla1* gene a perfectly aligned repeat of the pentamer GGGGC was found. Very

short direct repeats in adjacent introns are able to mediate exon duplication (Chen et al., 2005). The *cincinnati* mouse, indeed, shows two tandem copies of the 83 bp exon 5. This exon duplication in *Gla1* transcript results in a frameshift mutation with a novel generated premature stop codon (F159X) followed by a loss of GlyR $\alpha 1$ function comparable to the *oscillator* mutant. The predicted protein lacks the C-terminal 271 residues of the GlyR $\alpha 1$ protein. Thus, exon duplication is a common process contributing significantly to the evolution of functional complexity in the genome. Large deletions have also been observed in humans suffering from hyperekplexia with a deletion of exons 1–7 (Becker et al., 2006). Here, a complete loss of GlyR $\alpha 1$ is, however, much better tolerated by the human organism arguing for different compensation routes in humans compared to mice.

THE SPASTIC MOUSE MUTANT—AN ABERRANT SPLICING MUTATION

Homozygous *spa* mice manifest at the postnatal age of 2 weeks hyperekplexia-like severe neuromuscular symptoms, such as exaggerated startle response, rapid tremor, myoclonus, rigidity, and impaired righting reflex (Figure 2, Table 1) (Becker, 1990; Kingsmore et al., 1994; Mulhardt et al., 1994).

An insertion of a repetitive LINE1 element in intron 6 of the *Glr β* gene at chromosome 3 is the genetic reason for the neuromotor phenotype in *spa/spa* mice. This mutation leads to deficient mRNA splicing with functional β mRNA levels being decreased to approximately 10% (Kingsmore et al., 1994; Mulhardt et al., 1994). The mouse GlyR β subunit is encoded on chromosome 3q. The β subunit of the GlyR is known to be an important structural component of the pentameric GlyR complex for its synaptic location. Clustering of GlyRs at postsynaptic sites is enabled via an interaction of a binding motif in the intracellular TM3-4 loop of the β subunit to the scaffolding protein gephyrin. Moreover, recently it has been shown that GlyR β is also involved in ligand binding, yet with low affinity (Grudzinska et al., 2005; Duterre et al., 2012). It has been reported that within litters mild as well as severe phenotypes of homozygous *spa/spa* animals exist. A different level of mRNA expression has been ruled out (Molon et al., 2006). Following a differentiation of *spa/spa* animals into three groups, mice with early stage (M.e.s.), mice with recovery stage (M.r.s.), and severe phenotype (Sev), a compensatory effect with an up-regulation of the GlyR $\alpha 1$ mRNA has only been found for older recovered mice (M.r.s.) concomitantly with a higher GlyR $\alpha 1$ protein amount. In contrast, an up-regulation of the fetal glycine receptor GlyR $\alpha 2$ could never be observed. The higher amount of GlyR $\alpha 1$ protein can be one possible mechanism of compensation of GlyR β loss accompanied by functional recovery observed in these mice, respectively. Furthermore, in mice with a severe phenotype apoptosis together with the loss of glycinergic interneurons in the ventral horn of the spinal cord have been found followed by a dramatic loss of MNs. Last could explain the paralysis and early death of these homozygous *spa/spa* population (Molon et al., 2006). Functional data from recordings in brainstem slices containing the hypoglossal nuclei further support this observation. Graham et al. have demonstrated that in *spa/spa* mice glycinergic inhibition in hypoglossal MNs is decreased without a dramatic change in receptor kinetics; however, whole-cell GlyR currents were picrotoxin sensitive. Picrotoxin-sensitivity did




FIGURE 4 | GlyRs re-constituted from independent folding domains (modified from Villmann et al., 2009a). Rescue of function experiments of spd^{ot} constructs compared with truncated $\alpha 1$ variants. Using whole-cell recordings from transfected HEK293 cells, maximal glycine (gly)-gated currents were determined with 3 mM glycine: **(A)** $\alpha 1A$ wt; **(B)** $\alpha 1A$ wt blocked with strychnine (stry); **(C)** $\alpha 1A$ -trc, spd^{ot} -trc and spd^{ot} -elg when expressed alone generated non-functional channels; **(D)** $\alpha 1A$ -trc plus myc- $\alpha 1$ -iD-TM4 restored functionality and was antagonized with strychnine **(E)**; **(F)** spd^{ot} -trc plus myc- $\alpha 1$ -iD-TM4 restored functional GlyRs but with less efficiency compared to $\alpha 1$ -trc; **(G)** spd^{ot} -elg plus myc- $\alpha 1$ -iD-TM4

never generated functional channels. **(H)** Spinal cord neurons were infected with C-terminal domain constructs encoded on a pAAV vector. Comparison of infected (DIV21; bottom) and uninfected spinal cord neurons isolated from either homozygous wild type (+/+) or *oscillator* (*ot/ot*) mice (DIV21 uninfected). The $\alpha 1$ -antibody Mab2b recognizes only the $\alpha 1$ variant, whereas pan- α recognizes all GlyR α variants. After infection with different constructs (myc- $\alpha 1$ -iD-TM4, pc- $\alpha 1$ -iD-TM4-myc, or $\alpha 1$ -iD-TM4) infected neurons expressed endogenous GlyR $\alpha 1$ protein (bottom 3 panels, right pictures, depicted in red) that co-localized (merged pictures) with the appropriate C-terminal domains.

not result from homomeric GlyR $\alpha 2$ or GABAergic compensation as upregulation of GlyR $\alpha 2$ was not observed and all measurements have been performed in the presence of GABA_A receptor antagonist bicuculline. Thus, at least a distinct proportion of GlyRs in *spastic* mice results from homomeric GlyR $\alpha 1$ receptors. A synaptic location of homomeric $\alpha 1$ clusters was excluded since GlyR-mediated evoked IPSCs from *spa/spa* and wild type animals showed the same picrotoxin sensitivity (Graham et al., 2006). Furthermore, a decrease in GlyR number at synaptic sites has been shown by different approaches, such as immunohistochemical or biochemical stainings (Becker et al., 1986; Callister et al., 1999). The described examinations so far only concentrated on the postsynaptic site of the glycinergic synapse. Muller et al. considered presynaptic effects in *spa/spa* mice. In the developing hypoglossal nucleus of *spastic* mice glycinergic presynaptic terminals decreased during the first two postnatal weeks whereas

GABAergic terminals increased. In contrast, glycinergic terminals increase in inhibitory synapses in wild type mice during the same developmental period. Although this presynaptic adaptation of neurotransmitter content in response to the decrease of GlyR β at the postsynaptic membrane demonstrates a crosstalk between pre- and postsynaptic elements in *spastic* mice, the observed GABAergic upregulation was not sufficient to compensate for defective glycinergic neurotransmission (Muller et al., 2008).

Interestingly, the reduced expression of GlyR β at the protein level can be rescued by transgenic expression of an exogenous rat GlyR β minigene. This minigene construct contained a rat GlyR β cDNA, which was cloned into an expression vector suitable for driving brain-specific expression under the control of the rat neuron-specific enolase promoter (NSE). With this minigene a higher protein expression (approximately 25%) of full-length

GlyR β could be reached and a rescue of the symptoms has been observed (Hartenstein et al., 1996).

Homozygous mice (*spa/spa*) with a C57BL/6J (B6) background have strong symptoms and die at about 3 weeks after birth, while *spa/spa* animals of the backcross strain F1(C57BL/6J \times C3H/HeJ) \times C57BL/6J (C3H) show milder symptoms and mostly survive the critical age (von Wegerer et al., 2003). With ageing, these animals develop joint contractures and a vertebral arthropathy (Ziv et al., 1984), but their anatomical structures in spinal cord, CNS, or muscles are not altered or changed. The C3H/HeJ mouse strain seems to harbor an additional splicing factor or another modifying candidate gene, which enables *spa/spa* mice to sustain life. Very recently, a short nucleotide polymorphism (SNP) was localized in *Glrb* exon 6 at an exonic splicing enhancer (ESE) site, regulating exon skipping in *Glrb*. This ESE site is a binding site of the essential splicing regulatory protein SRSF1. Furthermore, the 5' and 3' UTR of the LINE1 were shown to be critical determinants for exon skipping, indicating that the LINE1 represents an efficient modifier of endogenous splicing phenotypes (Becker et al., 2012).

THE *Nmf11* MUTATION—AN ENU INDUCED POINT MUTATION

Nmf11 homozygous mice show an *oscillator*-like phenotype with an early death within 3 weeks after birth. In contrast to *oscillator*, the *Nmf11* mutation was chemically induced by a powerful chemical mutagen N-ethyl-N-nitrosourea (ENU). ENU is used to induce point mutations genome-wide with a high frequency. The *Nmf11* mutation in mice courses a C-to-A transition of nucleotide 138, which results in the N46K substitution in the long extracellular N-terminal ligand-binding domain of the *Gla1* mature protein (Figure 2, Table 1) (Traka et al., 2006). The mutation does not affect *Gla1* mRNA and protein levels nor does it block the correct membrane targeting of the protein given that substantial amounts of the receptor were detected at synaptic sites of *Nmf11* homozygotes. The mechanism by which the *Nmf11* mutation impairs GlyR function is currently unknown. The mode of actions could either be due to differences in ligand binding or gating, respectively (Traka et al., 2006). Disturbances in receptor assembly seemed to be unfavorable, as well as a defect in oligomerization. The latter has been shown to be dependent on TM4 and aromatic residues within the other TMs (Haeger et al., 2010).

KNOCK-OUT GLYR MOUSE MUTANTS

A commonly used strategy to investigate the physiological role and significance of proteins is the generation of corresponding knock-out animals. Thereby the animal becomes deficient of the desired protein within either specific cell types or organs (conditional knock-out) or throughout the whole organism. Concerning the glycinergic system of inhibitory neurotransmission a variety of knock-out mice exist displaying deficiency of either the $\alpha 2$ or $\alpha 3$ subunit of the inhibitory GlyR. Naturally occurring mutations of the murine GlyR $\alpha 1$ subunit, as in the spontaneous mouse mutant *oscillator*, lead to loss of the respective protein, thus resembling the knock-out $\alpha 1$ situation (Kling et al., 1997). The absence of GlyR $\alpha 1$ exhibits the most severe phenotype since it is the subunit that is primarily responsible for

glycinergic inhibition in the adult animals. It is widely expressed in brain stem and spinal cord, where the neuronal control of excitability is enabled by synaptic $\alpha 1\beta$ heteromeric GlyR clusters. In contrast, deletions of either the GlyR $\alpha 2$ or $\alpha 3$ subunits resulted in mild phenotypes with no major morphological or molecular disturbances compared to *oscillator mice* (Harvey et al., 2004; Young-Pearse et al., 2006). Both knock-out mice will be discussed in more detail with regard to possible compensatory mechanisms.

Gla2 KNOCK-OUT MICE

The *Gla2* gene encodes the $\alpha 2$ subunit of the inhibitory GlyR. Two different variants $\alpha 2A$ and $\alpha 2B$ are known to be generated by alternative splicing (Kuhse et al., 1991). This subunit is capable of forming functional homopentameric receptors *in vivo*, which represent the embryonic and early postnatal form of glycinergic neurotransmission. The embryonic configuration is expressed throughout the nervous system and presumably located extrasynaptically (Flint et al., 1998). Moreover, due to the embryonic chloride ion distribution over the cell membrane, the $\alpha 2$ homopentameric receptors display an excitatory mode of action leading to a rise in intracellular calcium concentration (Flint et al., 1998). GlyR $\alpha 2$ homomeric receptors display a lower agonist affinity to glycine as compared to the $\alpha 1$ homopentamer. The potency of the agonists glycine, β -alanine and taurine has been described to be higher for the $\alpha 2B$ variant (Miller et al., 2004). Mangin et al. investigated the kinetic properties of the $\alpha 2$ homopentameric GlyR at the single channel level. The homomeric $\alpha 2$ receptor type is slower by one or two orders of magnitude as compared to the $\alpha 1/\beta$ heteropentameric receptor involved in synaptic glycinergic neurotransmission (Mangin et al., 2003). This was reflected by a slow onset, relaxation and desensitization and a low open probability upon synaptic-like application of glycine. These physiological characteristics render the $\alpha 2$ homomeric receptor inefficient for fast synaptic activation but comparatively suitable for activation via sustained and slow release of the agonist (Mangin et al., 2003).

Making use of *Gla2* knock-out mice the importance of this specific GlyR subunit for neuronal development during embryogenesis as well as for normal CNS function during adulthood has been investigated. First, there is no overt phenotype accompanied by the loss of the $\alpha 2$ subunit. The knock-out mice resemble normal weight compared to their wildtype littermates. Their life expectancy is unchanged and fertility is also not affected in the absence of the GlyR $\alpha 2$ subunit (Young-Pearse et al., 2006; Weiss et al., 2008). Young-Pearse et al. have investigated potential morphological alterations upon knock-out of GlyR $\alpha 2$. No striking abnormalities concerning the development and shape of spinal cord, cortex and retina have been found. Diameter and cell density of knock-out spinal cords were undistinguishable from the wild type situation. Calcium uptake studies of embryonic and neonatal cortical brain slices derived from knock-out animals confirmed the absence of functional GlyRs at that stage of development. While glycine had no effect on calcium uptake, stimulation by GABA induced a rise of intracellular calcium levels confirming unaltered GABAergic activity. The loss of glycinergic response was recovered at day P7 probably by expression of

other GlyR subunits. However, despite the deficiency of electrophysiological responses to GlyR agonists such as glycine and taurine, the morphological development of cortices and cerebelli in knock-out animals seems to be unaltered (Young-Pearse et al., 2006).

In addition to its important role in brain stem and spinal cord, glycine also acts, besides GABA, as an inhibitory neurotransmitter in the neuronal networks of the retina (Pourcho, 1996) where it has been found in 40–50% of all amacrine cells (Marc, 1989). Within the variety of glycinergic amacrine cells, all α -subunits have been identified in specific synapses (Sasso-Pognetto et al., 1994; Haverkamp et al., 2003, 2004; Heinze et al., 2007). Immunoreactivity of the GlyR α 2 subunit was found to be evenly distributed across the inner plexiform layer representing the most frequent type of GlyRs in this area (Haverkamp et al., 2004).

***Gla3* KNOCK-OUT MICE**

The *Gla3* gene encodes the GlyR α 3 subunit, which can be found within several regions of the CNS. Concerning its appearance in the spinal cord, it is evenly distributed throughout the superficial and deep laminae of the dorsal horn (Anderson et al., 2009). With the help of immunohistochemical experiments Harvey et al. could show that the GlyR α 3 subunit can be co-stained predominantly in laminae II with gephyrin, which is necessary for synaptic localization. Moreover, it could also be co-stained with the α 1 subunit of the GlyR, indicating that in these laminae II both subunit-specific glycinergic synapses exist, which contain either α 1 or α 3 and mixed synapses containing both α 1 and α 3. Lamina II is the brain region where most nociceptive afferent fibers terminate, which are involved in pain pathways (Harvey et al., 2004). Concerning these pathways, following prostaglandin E2 (PGE2) application a dramatic reduction in glycinergic inhibition of neurons within the dorsal horn of rat spinal cord, the first site of synaptic integration in the pain pathway was observed (Ahmadi et al., 2002). In turn, PGE2 levels increase in the CNS upon peripheral inflammation (Samad et al., 2001). First electrophysiological experiments with human embryonic kidney cells expressing the murine PGE2 receptor EP2 as well as the murine GlyR α 3 or a mutant lacking a PKA consensus sequence revealed the putative mechanism of PGE2 activity via phosphorylation and thereby inhibition of GlyR α 3. It has been demonstrated that GlyR α 3 is selectively involved in spinal nociceptive processing. During inflammatory pain states, PGE2 disinhibits via this mechanism the spinal transmission of nociceptive input throughout the spinal cord dorsal horn to higher brain areas (Harvey et al., 2004). This signal cascade leads to a sensitization of primary afferents, thereby lowering thresholds for neuronal activation and increasing nociceptor responsiveness. The observed phenotype results in increased responses to noxious stimulation termed hyperalgesia, and allodynia where normally non-noxious stimuli such as cooling, gentle touch, movement, and pressure are now perceived as being painful (Harvey et al., 2009). Understanding the role of GlyR α 3 in pain processing pathways opened a new therapeutic window to use the α 3 subunit as a target for treatment of chronic inflammatory pain. Ideally, therapeutic interventions could selectively increase the activity of GlyRs containing α 3,

which are down regulated via phosphorylation in inflammatory pain. Therefore and to get more insights into pain pathways an animal model was created: the *Gla3* knock-out mouse (Harvey et al., 2004).

Knock-out of the GlyR α 3 subunit in mice, however, showed no obvious phenotype and was compatible with life. These mice normally gain regular body weight and display no histopathological abnormalities in brain and spinal cord. Moreover, no alterations in posture, activity, gait, motor coordination, tremor, and startle response have been observed (Harvey et al., 2004). Further studies have been carried out to characterize GlyR α 3 knock-out mice concerning aspects of neurotransmission with regard to the sensation of different kinds of pain. Chronic pain can be broadly categorized into three types: inflammatory, neuropathic, and dysfunctional. Inflammatory pain arises from tissue damage and is associated with conditions such as arthritis. Neuropathic pain can arise from trauma in peripheral or CNS as a consequence of stroke or ischemia. The last type, dysfunctional pain, is a type of neural dysfunction like migraine characterized by a non-localized diffuse pain unaccompanied by either inflammation or nerve damage (Harvey et al., 2009). Experiments with α 3 knock-out mice concerning the role of this GlyR subunit in different pain pathways also show that the inhibition of glycinergic neurotransmission by PGE2 does not contribute to neuropathic pain after peripheral nerve injury. This supports the idea that inflammatory and neuropathic pain involve different mechanisms of central sensitization (Hosl et al., 2006). To get more insights Harvey et al. investigated GlyR α 3 and its potential role in other clinically relevant pain models as well as in neuropathic and visceral pain. GlyR α 3^{-/-} showed no difference in the induction of thermal pain sensitization following CFA injection, but recovered much more quickly compared to the wild type. Yet, there is no clear role in other inflammatory (treatment with capsaicin and carrageenan), neuropathic or visceral pain models. Thus, GlyR α 3 may play an important role in mediating PGE2 induced sensitization, but only in certain pain states (Harvey et al., 2009). Experiments concerning development of GlyR α 3 synapses contribute to previous findings. Any basal nociceptive hypersensitivity is absent in GlyR α 3^{-/-} mice, but GlyR α 1 is still available for mediating synaptic inhibition at lamina II synapses but cannot be modulated by PGE2 signaling cascade (Rajalu et al., 2009).

KNOCK-IN MOUSE MUTANTS

The approach of knock-in mice represents a powerful tool to look for physiological effects *in vivo* (Crestani et al., 2001). Knock-in mice have been generated to analyze the zinc modulation of inhibitory neurotransmission, which has been attributed to several residues in the N-terminus of GlyR α 1 (Laube et al., 1995). Zn²⁺ homeostasis is thought to be important for brain development and function. Both, current responses of excitatory as well as inhibitory ligand-gated ion channels have been shown to be modulated by Zn²⁺ (Smart et al., 2004). Neutralization of aspartate 80 (D80) with a glycine or alanine eliminated Zn²⁺ potentiation of the glycine-gated responses (Lynch et al., 1998; Laube et al., 2000). Homozygous mice carrying the D80A mutation displayed a neuromotor phenotype with an increased muscle tone

and massive tremor around P12, which persisted into the adulthood similar to that observed for the spontaneous mouse mutants *spasmodic* and *spastic*. In homozygous knock-in D80A mice (Hirzel et al., 2006) the potentiating effect of Zn^{2+} on glycine-gated currents recorded from cultured spinal cord neurons was reduced but not abolished using low concentrations. High concentrations of Zn^{2+} did not affect glycinergic inhibition. The residual Zn^{2+} potentiation observed in D80A knock-in mice may be due to other GlyRs than the $\alpha 1$ subunit. Immunocytochemical stainings showed massive labeling of extrasynaptic GlyR $\alpha 2$ arguing for residual Zn^{2+} potentiation via nonsynaptic GlyRs (Laube et al., 1995; Hirzel et al., 2006).

To study the pathomechanisms of human hyperekplexia in mice, Becker et al. introduced a human dominant mutation tg271Q into the *Gla1* gene (Becker et al., 2002). Binding of the high affinity antagonist strychnine was unaffected, but glycine affinity was reduced in spinal cord of tg271Q. Similarly, *in vitro* studies on R271Q demonstrated decreased agonist affinity accompanied with diminished glycine-gated currents (Langosch et al., 1994; Rajendra et al., 1994). Whole-cell patch-clamp studies showed a decrease in glycinergic neurotransmission to 69%. Interestingly, amplitudes of electrically evoked IPSCs from spinal cord neurons were also reduced for GABA_A-receptor-mediated currents, which was not due to a lower level of GABA_A receptor expression. Transgenic animals developed spontaneous tremor episodes from postnatal day 14 on with exaggerated startle responses to noise or touch. These data showed for the first time that a hyperekplexia-like phenotype is specific for the hyperekplexia associated mutated GlyR transgene. Besides the importance of GlyRs for motor coordination, these receptors are also targets for ethanol, longer chain alcohols and anaesthetics. Ethanol enhances glycine-gated responses and leads to loss of the righting reflex (LORR) in mice (Findlay et al., 2002). This effect can be antagonized with the glycine antagonist strychnine (Williams et al., 1995). Several *in vitro* studies led to the identification of distinct residues involved in ethanol potentiation (Mihic et al., 1997). S267N located in the ion channel pore is one of the key residues for ethanol modulation and has also been found in patients that suffer from hyperekplexia (Becker et al., 2008). This mutant displayed differences in agonist potency as well as ethanol modulation and demonstrated that a disease-associated *Gla1* mutation harbors the ability to alter drug responses. Similarly, the potentiating effect of ethanol was highly diminished in S267N knock-in mice. In contrast to the *oscillator* mutation, GlyR $\alpha 1$ protein expression in S267N knock-in animals was indistinguishable from wild-type levels. Glycine responses measured by uptake of glycine-stimulated chloride uptake from synaptoneurosomes from spinal cord and brainstem were decreased in heterozygous animals but comparable to heterozygous *oscillator* mice (Findlay et al., 2003). Muscimol-stimulated $^{36}Cl^{-}$ uptake was unchanged arguing that GABA_A receptor activity stayed unaffected. Thus, GABA_A receptors are not attributable for a compensatory effect of the disturbed GlyR inhibition (Findlay et al., 2003). Behavioral tests, however, displayed an enhanced acoustic startle response (Findlay et al., 2005). Moreover, homozygous S267N knock-in mice resulted in lethality 3 weeks after birth similar to the functional null mutation (Kling et al., 1997; Findlay et al., 2003). This

observation provided the first evidence that a point mutation does have a similar impact on the phenotype as the null allele. Homology analysis with mutated GlyRs on the GLIC structure searching for other amino acids, which are modulated by ethanol came up with two more candidates Q266I and M287L (Blednov et al., 2012; Borghese et al., 2012). Residue Q266 has also been found in a patient suffering from hyperekplexia (Milani et al., 1996). In knock-in mice both residues behave different to ethanol modulation. M287L reduces ethanol potentiation whereas Q266I abolished the ethanol potentiating effect. Physiological levels of Zn^{2+} have been shown to enhance ethanol potentiation of glycine-gated responses (McCracken et al., 2010). Although Zn^{2+} potentiation of glycine responses was unaffected, Zn^{2+} potentiation of the ethanol response was abolished in M287L. Glycine-induced maximal currents were reduced in isolated brain stem neurons similar to measurements in *Xenopus* oocytes. In addition, ethanol potentiation was absent in brainstem neurons isolated from homozygous knock-in mice. Radioligand binding assays demonstrated a reduced displacement of glycine by strychnine for knock-in animals, but flunitrazepam binding was not affected similar to previous findings in S267N knock-in mice (Borghese et al., 2012). These data again argue for lack of GABAergic compensation in GlyR-deficient mouse models. Behavioral characterization demonstrated an enhanced acoustic startle response for both mutants Q266I and M287L as observed for S267N, which is a hallmark for disturbances in glycinergic inhibition (Findlay et al., 2005; Blednov et al., 2012). A progressive phenotype starting from postnatal day 10 with massive muscle tremor and loss of motor control resulted in lethality between the 3 (Q266I) and 14 weeks (M287L) of life.

RECEPTOR ASSEMBLY FROM INDEPENDENTLY FOLDING DOMAINS

Receptor domains display high homology to other kinds of proteins, which exhibit different functions in their natural surrounding. The N-terminal part of CLRs for example shows high homology to the AchBP from the snail *Lymnaea stagnalis* (Brejč et al., 2001). Similarly, the excitatory glutamate receptors represent a mosaic with homology of the ligand binding domains to bacterial periplasmic binding proteins (LAOBP, lysine-arginine-ornithine binding protein and LIVBP, leucine-isoleucine-valine binding proteins). LIVBP homology has been found in the far N-terminal domain of GluRs important for receptor assembly. In addition, the pore domain represents high homology to the ion channel domain of K⁺ channels (Villmann and Becker, 2007). Several studies on domain swapping have shown that homologous domains can be exchanged between different receptor subclasses without dramatic changes in ion channel properties (Strutz et al., 2002; Hoffmann et al., 2006; Villmann et al., 2008). Reconstitution of functionality from independent folding domains seemed to be a chance to gain-of-function for truncated receptor proteins. The mouse mutant *oscillator* was used as a model system since the underlying mutation, a microdeletion, results in a premature STOP codon. This mouse mutant represents a functional null allele (Kling et al., 1997). *In vitro* experiments demonstrated that the coexpression of truncated receptor protein together with an independent “tail” construct

representing the lacking proportion of the GlyR α 1 protein, most of the TM3-4 loop, TM4, and the C-terminus rescued the GlyR function to about 10–50% of wild type activity. An infection of spinal cord neurons isolated from homozygous oscillator mice with an adeno-associated viral vector encoding the independent tail construct induced an expression of the α 1 antigen compared to uninfected cells lacking α 1 expression (**Figure 4**) (Villmann et al., 2009a).

This view on GlyR assembly from different folding domains toward a functional receptor will be a useful tool for restoration of ion channel function in other kinds of diseases such as the idiopathic generalized epilepsies, where mutations in genes encoding the postsynaptic inhibitory GABA_A receptor subunits resulting in protein truncation have been identified.

POSSIBLE ROUTES OF COMPENSATION

Mutations in GlyR genes *Gla1* and *GlrB* result in a neuromotor phenotype similar to patients suffering from hyperekplexia. That is why mice serve as excellent models for this human neuromotor disorder. The variety of mutations in mice comprises point mutations, microdeletions, duplications, and insertions. Human patients usually get treated with clonazepam, which helps via an enhancement of GABAergic responses to compensate for the lack or decrease of glycinergic inhibition. Although GABAergic compensation is also favored in mice, different experiments failed to show GABAergic upregulation at the level of expression. No changes in radioligand binding studies using brainstem or spinal cord membrane preparation from tissue have been observed meaning that the number of GABA_A receptors expressed in these membranes is unchanged (Becker et al., 2002; Blednov et al., 2012). Pharmacological studies on knock-in mice demonstrated that GABA_A receptor modulators such as flurazepam and pentobarbital induced an increase in LORR in addition to an increase in GlyR sensitivity to pentobarbital. Also picrotoxin-induced convulsions differed in knock-in mice suggesting changes in GABA_A receptor function (Blednov et al., 2012). An enhancement of GABAergic maximal current amplitudes has been shown in *spastic* mice, but in knock-in mice no functional differences were observed for GABA_A receptors (White and Heller, 1982; Findlay et al., 2003). Other compensatory effects via nAChR or NMDA receptors analyzed by ketamine or ethanol action used in behavioral studies of GlyR knock-in mice are difficult to interpret as these modulators at various concentrations act also directly on these classes of ligand-gated ion channels. What we have learned from knock-in mice is that there is very limited or no compensation. Moreover, *in vitro* studies on a human mutation with moderate effects on GlyR functionality could result in a severe impairment of glycinergic neurotransmission associated by lethality *in vivo*.

For the spontaneous mutations affecting one of the GlyR subunits present in the adult receptor complex, α 1 or β , compensatory mechanisms have been described in detailed physiological recordings. The rise and decay times of mIPSCs were similar between *spa/spa* and controls. Therefore, changes in GlyR distribution seem unlikely, but the lower frequency is in line with less α 1 β clusters due to lower transcription rate of full-length β subunits. Compensation in *spa/spa* via homomeric α 1

was favored as one possible mechanism; however, such homomeric α 1 receptors have never been observed at synaptic sites (Graham et al., 2006). As a consequence of low GlyR β numbers at the postsynaptic side in *spastic* mice, glycinergic presynaptic terminals decrease demonstrating an adaptation process the second postnatal week (Muller et al., 2008). Recently, Becker et al. have demonstrated that mouse line background could also have a compensatory effect on the appearance of the *spastic* phenotype. In addition to the insertion of a LINE1 element in intron 6 of the *GlrB* gene resulting in changes in endogenous splicing, a SNP in exon 6 functions as an ESE important for binding of the splice factor SRSF1. Minigene experiments showed that mis-splicing of the β -subunit could be rescued by the A/G transition in exon 6 present in the C3H/HeJ mouse background but absent in C57BL/6J where the *spastic* mutation was originally described (Becker et al., 2012). In *ot/ot* animals slow mIPSCs with very low amplitudes suggest some remaining GlyR clusters present at distal dendritic locations. Although the expression of α 2, α 3, and α 4 in *oscillator* is normal, the compensatory GlyR clusters are not sufficient to sustain life (Graham et al., 2006). In summary, some sort of compensation seem to exist in various mouse models for hyperekplexia, but neither upregulation of GABAergic responses nor compensation by other GlyR subunits are able to rescue glycinergic dysfunction in mouse spinal cord. Thus, disturbances in glycinergic inhibition perturb a neuronal network with the GlyR playing a key role in this network.

CONCLUSIONS

Functional inhibitory GlyRs are important for neuromotor behavior. Disturbances in the glycinergic synaptic circuit lead to severe startle reactions in response to tactile or acoustic stimuli. Spontaneous mutations and knock-in mice carrying human hyperekplexia mutations serve as models to understand the human neuromotor phenotype. But why do some mutations in the GlyR genes (*Gla1* or *GlrB*) in rodents result in a mild and others in a lethal phenotype? Are there differences in compensatory mechanisms? The strength of a phenotype could result from mouse line background as recently shown for the two hit splice mutation in the mouse mutant *spastic*. Furthermore, the functional effect depends on the location of the mutation. Here, the increasing knowledge on the molecular structure of CLRs during the last decade opened novel windows for an interpretation of functional data with the help of homologous models. Interestingly, knock-out mice of the GlyR α 2 or α 3 demonstrated normal life span. In contrast, the functional null allele of the *Gla1* gene resulted in lethality at the age of 3 weeks when the developmental shift toward the adult receptor complex α 1 β is completed. Therefore, there is no doubt that heteromeric α 1 β GlyRs play the most important role for fast inhibitory neurotransmission processes in motor function. So far premature truncation of GlyR α 1 could only be compensated when the lacking protein proportion was coexpressed at least *in vitro*. An assembly of functional GlyRs from independent domains seems to overcome processes like nonsense-mediated decay or when translated ER-mediated degradation. But the existence of similar coordinated assembly processes *in vivo* has to be proven. According

to the human mutations, all described GlyR α 1 knock-in studies exhibited similar functional differences on GlyRs compared to *in vitro* data obtained from either transfected cell lines or oocyte recordings. Thus, mice seem to be an excellent model system to study hyperekplexia. Mice carrying human mutations showed an onset of symptoms as massive tremor and startle attacks with the age of 15 days when developmental changes in GlyR subunit composition are almost completed. Treatment of human patients with clonazepam favored an up-regulation of the GABAergic neurotransmission. Therefore, most studies looking for compensatory mechanisms in mice concentrated on the receptor configuration at the postsynaptic side. All physiological studies so far have, however, strikingly shown that the central role of the adult isoform α 1 β cannot be compensated by another GlyR receptor configuration neither by α 3 β , homomeric α 1, α 2 nor distinct GABA_A receptors. Although there is still requirement to search for subunit-specific blockers of either α 1, or α 2, or α 3, and β , to improve the interpretation of physiological data, our knowledge on the differences in the kinetics of GlyR subpopulations has amazingly increased during the last years. Yet, the complexity of synaptic circuits *in vivo* as well as synaptic adaptation processes are far away from being understood. One future direction of research is trying to identify so

far unknown regulatory elements or proteins responsible for synaptic adaptation at the inhibitory synapses during glycinergic disturbances. It has been shown that presynaptic terminals and postsynaptic elements communicate with, e.g., an adaptation of less presynaptic glycinergic terminals in response to less GlyR β at the postsynapse in the mouse mutant *spastic*. GABAergic terminals instead increase but GABA_A receptor numbers stay unaffected. The various mouse models discussed here demonstrate that the current hypothesis of GABAergic compensation for a failure in glycinergic neurotransmission has to be carefully scrutinized. An enhancement of the GABAergic responses by treatment with clonazepam is therefore unlikely to explain the massive improvement of symptoms observed in human patients. Thus, the described mouse models in combination with modern imaging techniques and proteomics serve as excellent tools to close the gap between adaptation and remodeling of inhibitory synapses *in vivo* under physiological and pathological conditions.

ACKNOWLEDGMENTS

Research in our lab is supported by grants from the Deutsche Forschungsgemeinschaft (DFG VI586/1 to Carmen Villmann), EU Neurocypres, and the Johannes und Frieda Marohn Stiftung.

REFERENCES

- Ahmadi, S., Lippross, S., Neuhuber, W. L., and Zeilhofer, H. U. (2002). PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. *Nat. Neurosci.* 5, 34–40.
- Allain, A. E., Bairi, A., Meyrand, P., and Branchereau, P. (2006). Expression of the glycinergic system during the course of embryonic development in the mouse spinal cord and its co-localization with GABA immunoreactivity. *J. Comp. Neurol.* 496, 832–846.
- Alvarez, F. J., and Fyffe, R. E. (2007). The continuing case for the Renshaw cell. *J. Physiol.* 584, 31–45.
- Andermann, F., Keene, D. L., Andermann, E., and Quesney, L. F. (1980). Startle disease or hyperekplexia: further delineation of the syndrome. *Brain* 103, 985–997.
- Anderson, W. B., Graham, B. A., Beveridge, N. J., Tooney, P. A., Brichta, A. M., and Callister, R. J. (2009). Different forms of glycine- and GABA(A)-receptor mediated inhibitory synaptic transmission in mouse superficial and deep dorsal horn neurons. *Mol. Pain* 5, 65.
- Baer, K., Waldvogel, H. J., During, M. J., Snell, R. G., Faull, R. L., and Rees, M. I. (2003). Association of gephyrin and glycine receptors in the human brainstem and spinal cord: an immunohistochemical analysis. *Neuroscience* 122, 773–784.
- Baer, K., Waldvogel, H. J., Faull, R. L., and Rees, M. I. (2009). Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review. *Front. Mol. Neurosci.* 2:25. doi: 10.3389/neuro.02.025.2009
- Balling, R. (2001). ENU mutagenesis: analyzing gene function in mice. *Annu. Rev. Genomics Hum. Genet.* 2, 463–492.
- Becker, C. M. (1990). Disorders of the inhibitory glycine receptor: the spastic mouse. *FASEB J.* 4, 2767–2774.
- Becker, C. M., Hermans-Borgmeyer, I., Schmitt, B., and Betz, H. (1986). The glycine receptor deficiency of the mutant mouse *spastic*: evidence for normal glycine receptor structure and localization. *J. Neurosci.* 6, 1358–1364.
- Becker, K., Braune, M., Benderska, N., Buratti, E., Baralle, F., Villmann, C., et al. (2012). A retroelement modifies pre-mRNA splicing: the murine *Glrbspa* allele is a splicing signal polymorphism amplified by long interspersed nuclear element insertion. *J. Biol. Chem.* 287, 31185–31194.
- Becker, K., Breiting, H. G., Humeny, A., Meinck, H. M., Dietz, B., Aksu, F., et al. (2008). The novel hyperekplexia allele *GLRA1(S267N)* affects the ethanol site of the glycine receptor. *Eur. J. Hum. Genet.* 16, 223–228.
- Becker, K., Hohoff, C., Schmitt, B., Christen, H. J., Neubauer, B. A., Sandrieser, T., et al. (2006). Identification of the microdeletion breakpoint in a *GLRA1* null allele of Turkish hyperekplexia patients. *Hum. Mutat.* 27, 1061–1062.
- Becker, L., von Wegerer, J., Schenkel, J., Zeilhofer, H. U., Swandulla, D., and Weiher, H. (2002). Disease-specific human glycine receptor α 1 subunit causes hyperekplexia phenotype and impaired glycine- and GABA(A)-receptor transmission in transgenic mice. *J. Neurosci.* 22, 2505–2512.
- Blednov, Y. A., Benavidez, J. M., Homanics, G. E., and Harris, R. A. (2012). Behavioral characterization of knockin mice with mutations M287L and Q266I in the glycine receptor α 1 subunit. *J. Pharmacol. Exp. Ther.* 340, 317–329.
- Bocquet, N., Nury, H., Baaden, M., Le Poupon, C., Changeux, J. P., Delarue, M., et al. (2009). X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. *Nature* 457, 111–114.
- Borghese, C. M., Blednov, Y. A., Quan, Y., Iyer, S. V., Xiong, W., Mihic, S. J., et al. (2012). Characterization of two mutations, M287L and Q266I, in the α 1 glycine receptor subunit that modify sensitivity to alcohols. *J. Pharmacol. Exp. Ther.* 340, 304–316.
- Breiting, H. G., Villmann, C., Melzer, N., Rennert, J., Breiting, U., Schwarzing, S., et al. (2009). Novel regulatory site within the TM3-4 loop of human recombinant α 3 glycine receptors determines channel gating and domain structure. *J. Biol. Chem.* 284, 28624–28633.
- Brejck, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van Der Oost, J., Smit, A. B., et al. (2001). Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. *Nature* 411, 269–276.
- Buckwalter, M. S., Cook, S. A., Davisson, M. T., White, W. F., and Camper, S. A. (1994). A frameshift mutation in the mouse α 1 glycine receptor gene (*Glr1*) results in progressive neurological symptoms and juvenile death. *Hum. Mol. Genet.* 3, 2025–2030.
- Calamai, M., Specht, C. G., Heller, J., Alcor, D., Machado, P., Vannier, C., et al. (2009). Gephyrin oligomerization controls GlyR mobility and synaptic clustering. *J. Neurosci.* 29, 7639–7648.
- Callister, R. J., Schofield, P. R., and Sah, P. (1999). Use of murine mutants to study glycine receptor function. *Clin. Exp. Pharmacol. Physiol.* 26, 929–931.
- Chalphin, A. V., and Saha, M. S. (2010). The specification of glycinergic neurons and the role of glycinergic transmission in development.

- Front. Mol. Neurosci.* 3:11. doi: 10.3389/fnmol.2010.00011
- Chen, J. M., Chuzhanova, N., Stenson, P. D., Ferec, C., and Cooper, D. N. (2005). Meta-analysis of gross insertions causing human genetic disease: novel mutational mechanisms and the role of replication slippage. *Hum. Mutat.* 25, 207–221.
- Crestani, F., Low, K., Keist, R., Mandelli, M., Mohler, H., and Rudolph, U. (2001). Molecular targets for the myorelaxant action of diazepam. *Mol. Pharmacol.* 59, 442–445.
- Dlugaiczky, J., Singer, W., Schick, B., Iro, H., Becker, K., Becker, C. M., et al. (2008). Expression of glycine receptors and gephyrin in the rat cochlea. *Histochem. Cell Biol.* 129, 513–523.
- Dutertre, S., Drwal, M., Laube, B., and Betz, H. (2012). Probing the pharmacological properties of distinct subunit interfaces within heteromeric glycine receptors reveals a functional betabeta agonist binding site. *J. Neurochem.* 122, 38–47.
- Findlay, G. S., Harris, R. A., and Blednov, Y. A. (2005). Male transgenic glycine receptor alpha1 (S267Q) mutant mice display a hyperekplexia-like increase in acoustic startle responses. *Pharmacol. Biochem. Behav.* 82, 215–222.
- Findlay, G. S., Phelan, R., Roberts, M. T., Homanics, G. E., Bergeson, S. E., Lopreato, G. F., et al. (2003). Glycine receptor knock-in mice and hyperekplexia-like phenotypes: comparisons with the null mutant. *J. Neurosci.* 23, 8051–8059.
- Findlay, G. S., Wick, M. J., Mascia, M. P., Wallace, D., Miller, G. W., Harris, R. A., et al. (2002). Transgenic expression of a mutant glycine receptor decreases alcohol sensitivity of mice. *J. Pharmacol. Exp. Ther.* 300, 526–534.
- Flint, A. C., Liu, X., and Kriegstein, A. R. (1998). Nonsynaptic glycine receptor activation during early neocortical development. *Neuron* 20, 43–53.
- Fritschy, J. M., Harvey, R. J., and Schwarz, G. (2008). Gephyrin: where do we stand, where do we go? *Trends Neurosci.* 31, 257–264.
- Gao, B. X., Stricker, C., and Ziskind-Conhaim, L. (2001). Transition from GABAergic to glycinergic synaptic transmission in newly formed spinal networks. *J. Neurophysiol.* 86, 492–502.
- Gonzalez-Forero, D., and Alvarez, F. J. (2005). Differential postnatal maturation of GABAA, glycine receptor, and mixed synaptic currents in Renshaw cells and ventral spinal interneurons. *J. Neurosci.* 25, 2010–2023.
- Graham, B. A., Schofield, P. R., Sah, P., Margrie, T. W., and Callister, R. J. (2006). Distinct physiological mechanisms underlie altered glycinergic synaptic transmission in the murine mutants spastic, spasmodic, and oscillator. *J. Neurosci.* 26, 4880–4890.
- Graham, B. A., Tadros, M. A., Schofield, P. R., and Callister, R. J. (2011). Probing glycine receptor stoichiometry in superficial dorsal horn neurons using the spasmodic mouse. *J. Physiol.* 589, 2459–2474.
- Greferath, U., Brandstatter, J. H., Wassle, H., Kirsch, J., Kuhse, J., and Grunert, U. (1994). Differential expression of glycine receptor subunits in the retina of the rat: a study using immunohistochemistry and *in situ* hybridization. *Vis. Neurosci.* 11, 721–729.
- Grudzinska, J., Schemm, R., Haeger, S., Nicke, A., Schmalzing, G., Betz, H., et al. (2005). The beta subunit determines the ligand binding properties of synaptic glycine receptors. *Neuron* 45, 727–739.
- Haeger, S., Kuzmin, D., Detro-Dassen, S., Lang, N., Kilb, M., Tsetlin, V., et al. (2010). An intramembrane aromatic network determines pentameric assembly of Cys-loop receptors. *Nat. Struct. Mol. Biol.* 17, 90–98.
- Hartenstein, B., Schenkel, J., Kuhse, J., Besenbeck, B., Kling, C., Becker, C. M., et al. (1996). Low level expression of glycine receptor beta subunit transgene is sufficient for phenotype correction in spastic mice. *EMBO J.* 15, 1275–1282.
- Harvey, R. J., Depner, U. B., Wassle, H., Ahmadi, S., Heindl, C., Reinold, H., et al. (2004). GlyR alpha3, an essential target for spinal PGE2-mediated inflammatory pain sensitization. *Science* 304, 884–887.
- Harvey, R. J., Schmieden, V., Von Holst, A., Laube, B., Rohrer, H., and Betz, H. (2000). Glycine receptors containing the alpha4 subunit in the embryonic sympathetic nervous system, spinal cord and male genital ridge. *Eur. J. Neurosci.* 12, 994–1001.
- Harvey, R. J., Topf, M., Harvey, K., and Rees, M. I. (2008). The genetics of hyperekplexia: more than startle! *Trends Genet.* 24, 439–447.
- Harvey, V. L., Caley, A., Muller, U. C., Harvey, R. J., and Dickenson, A. H. (2009). A selective role for alpha3 subunit glycine receptors in inflammatory pain. *Front. Mol. Neurosci.* 2:14. doi: 10.3389/fnmol.2010.00011
- Haverkamp, S., Muller, U., Harvey, K., Harvey, R. J., Betz, H., and Wassle, H. (2003). Diversity of glycine receptors in the mouse retina: localization of the alpha3 subunit. *J. Comp. Neurol.* 465, 524–539.
- Haverkamp, S., Muller, U., Zeilhofer, H. U., Harvey, R. J., and Wassle, H. (2004). Diversity of glycine receptors in the mouse retina: localization of the alpha2 subunit. *J. Comp. Neurol.* 477, 399–411.
- Heinze, L., Harvey, R. J., Haverkamp, S., and Wassle, H. (2007). Diversity of glycine receptors in the mouse retina: localization of the alpha4 subunit. *J. Comp. Neurol.* 500, 693–707.
- Hibbs, R. E., and Gouaux, E. (2011). Principles of activation and permeation in an anion-selective Cys-loop receptor. *Nature* 474, 54–60.
- Hilf, R. J., and Dutzler, R. (2008). X-ray structure of a prokaryotic pentameric ligand-gated ion channel. *Nature* 452, 375–379.
- Hilf, R. J., and Dutzler, R. (2009). Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel. *Nature* 457, 115–118.
- Hirzel, K., Muller, U., Latal, A. T., Hulsmann, S., Grudzinska, J., Seeliger, M. W., et al. (2006). Hyperekplexia phenotype of glycine receptor alpha1 subunit mutant mice identifies Zn(2+) as an essential endogenous modulator of glycinergic neurotransmission. *Neuron* 52, 679–690.
- Hoffmann, J., Villmann, C., Werner, M., and Hollmann, M. (2006). Investigation via ion pore transplantation of the putative relationship between glutamate receptors and K(+) channels. *Mol. Cell. Neurosci.* 33, 358–370.
- Holland, K. D., Fleming, M. T., Cheek, S., Moran, J. L., Beier, D. R., and Meisler, M. H. (2006). De novo exon duplication in a new allele of mouse Glra1 (spasmodic). *Genetics* 174, 2245–2247.
- Hosl, K., Reinold, H., Harvey, R. J., Muller, U., Narumiya, S., and Zeilhofer, H. U. (2006). Spinal prostaglandin E receptors of the EP2 subtype and the glycine receptor alpha3 subunit, which mediate central inflammatory hyperalgesia, do not contribute to pain after peripheral nerve injury or formalin injection. *Pain* 126, 46–53.
- Jonas, P., Bischofberger, J., and Sandkuhler, J. (1998). Corelease of two fast neurotransmitters at a central synapse. *Science* 281, 419–424.
- Kingsmore, S. F., Giros, B., Suh, D., Bieniarz, M., Caron, M. G., and Seldin, M. F. (1994). Glycine receptor beta-subunit gene mutation in spastic mouse associated with LINE-1 element insertion. *Nat. Genet.* 7, 136–141.
- Kling, C., Koch, M., Saul, B., and Becker, C. M. (1997). The frameshift mutation oscillator (Glra1(spdt-ot)) produces a complete loss of glycine receptor alpha1-polypeptide in mouse central nervous system. *Neuroscience* 78, 411–417.
- Kotak, V. C., Korada, S., Schwartz, I. R., and Sanes, D. H. (1998). A developmental shift from GABAergic to glycinergic transmission in the central auditory system. *J. Neurosci.* 18, 4646–4655.
- Kuhse, J., Kuryatov, A., Maulet, Y., Malosio, M. L., Schmieden, V., and Betz, H. (1991). Alternative splicing generates two isoforms of the alpha 2 subunit of the inhibitory glycine receptor. *FEBS Lett.* 283, 73–77.
- Kuhse, J., Laube, B., Magalei, D., and Betz, H. (1993). Assembly of the inhibitory glycine receptor: identification of amino acid sequence motifs governing subunit stoichiometry. *Neuron* 11, 1049–1056.
- Lane, P. W., Ganser, A. L., Kerner, A. L., and White, W. F. (1987). Spasmodic, a mutation on chromosome 11 in the mouse. *J. Hered.* 78, 353–356.
- Langosch, D., Laube, B., Rundstrom, N., Schmieden, V., Bormann, J., and Betz, H. (1994). Decreased agonist affinity and chloride conductance of mutant glycine receptors associated with human hereditary hyperekplexia. *EMBO J.* 13, 4223–4228.
- Laube, B., Kuhse, J., and Betz, H. (2000). Kinetic and mutational analysis of Zn2+ modulation of recombinant human inhibitory glycine receptors. *J. Physiol.* 522(Pt 2), 215–230.
- Laube, B., Kuhse, J., Rundstrom, N., Kirsch, J., Schmieden, V., and Betz, H. (1995). Modulation by zinc ions of native rat and recombinant human inhibitory glycine receptors. *J. Physiol.* 483(Pt 3), 613–619.
- Lynch, J. W. (2004). Molecular structure and function of the glycine receptor chloride channel. *Physiol. Rev.* 84, 1051–1095.
- Lynch, J. W. (2009). Native glycine receptor subtypes and their physiological roles. *Neuropharmacology* 56, 303–309.
- Lynch, J. W., Jacques, P., Pierce, K. D., and Schofield, P. R. (1998). Zinc potentiation of the glycine receptor chloride channel is mediated by

- allosteric pathways. *J. Neurochem.* 71, 2159–2168.
- Lynch, J. W., Rajendra, S., Pierce, K. D., Handford, C. A., Barry, P. H., and Schofield, P. R. (1997). Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel. *EMBO J.* 16, 110–120.
- Malosio, M. L., Grenningloh, G., Kuhse, J., Schmieden, V., Schmitt, B., Prior, P., et al. (1991a). Alternative splicing generates two variants of the alpha 1 subunit of the inhibitory glycine receptor. *J. Biol. Chem.* 266, 2048–2053.
- Malosio, M. L., Marqueze-Pouey, B., Kuhse, J., and Betz, H. (1991b). Widespread expression of glycine receptor subunit mRNAs in the adult and developing rat brain. *EMBO J.* 10, 2401–2409.
- Mangin, J. M., Baloul, M., Prado De Carvalho, L., Rogister, B., Rigo, J. M., and Legendre, P. (2003). Kinetic properties of the alpha2 homo-oligomeric glycine receptor impairs a proper synaptic functioning. *J. Physiol.* 553, 369–386.
- Marc, R. E. (1989). The role of glycine in the mammalian retina. *Prog. Retin. Res.* 8, 67–107.
- Matzenbach, B., Maulet, Y., Sefton, L., Courtier, B., Avner, P., Guenet, J. L., et al. (1994). Structural analysis of mouse glycine receptor alpha subunit genes. Identification and chromosomal localization of a novel variant. *J. Biol. Chem.* 269, 2607–2612.
- McCracken, L. M., Trudell, J. R., Goldstein, B. E., Harris, R. A., and Mihic, S. J. (2010). Zinc enhances ethanol modulation of the alpha glycine receptor. *Neuropharmacology* 58, 676–681.
- Meier, J., Juttner, R., Kirischuk, S., and Grantyn, R. (2002). Synaptic anchoring of glycine receptors in developing collicular neurons under control of metabotropic glutamate receptor activity. *Mol. Cell. Neurosci.* 21, 324–340.
- Meier, J. C., Henneberger, C., Melnick, I., Racca, C., Harvey, R. J., Heinemann, U., et al. (2005). RNA editing produces glycine receptor alpha3(P185L), resulting in high agonist potency. *Nat. Neurosci.* 8, 736–744.
- Mihic, S. J., Ye, Q., Wick, M. J., Koltchine, V. V., Krasowski, M. D., Finn, S. E., et al. (1997). Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. *Nature* 389, 385–389.
- Milani, N., Dalpra, L., del Prete, A., Zanini, R., and Larizza, L. (1996). A novel mutation (Gln266→His) in the alpha 1 subunit of the inhibitory glycine receptor gene (GLRA1) in hereditary hyperekplexia. *Am. J. Hum. Genet.* 58, 420–422.
- Miller, P. S., Harvey, R. J., and Smart, T. G. (2004). Differential agonist sensitivity of glycine receptor alpha2 subunit splice variants. *Br. J. Pharmacol.* 143, 19–26.
- Molon, A., Di Giovanni, S., Hathout, Y., Natale, J., and Hoffman, E. P. (2006). Functional recovery of glycine receptors in spastic murine model of startle disease. *Neurobiol. Dis.* 21, 291–304.
- Mulhardt, C., Fischer, M., Gass, P., Simon-Chazottes, D., Guenet, J. L., Kuhse, J., et al. (1994). The spastic mouse: aberrant splicing of glycine receptor beta subunit mRNA caused by intronic insertion of L1 element. *Neuron* 13, 1003–1015.
- Muller, E., Le Corrionc, H., Scain, A. L., Triller, A., and Legendre, P. (2008). Despite GABAergic neurotransmission, GABAergic innervation does not compensate for the defect in glycine receptor postsynaptic aggregation in spastic mice. *Eur. J. Neurosci.* 27, 2529–2541.
- Muller, E., Le Corrionc, H., Triller, A., and Legendre, P. (2006). Developmental dissociation of presynaptic inhibitory neurotransmitter and postsynaptic receptor clustering in the hypoglossal nucleus. *Mol. Cell. Neurosci.* 32, 254–273.
- Nabekura, J., Katsurabayashi, S., Kakazu, Y., Shibata, S., Matsubara, A., Jinno, S., et al. (2004). Developmental switch from GABA to glycine release in single central synaptic terminals. *Nat. Neurosci.* 7, 17–23.
- Nikolic, Z., Laube, B., Weber, R. G., Lichter, P., Kioschis, P., Poustka, A., et al. (1998). The human glycine receptor subunit alpha3. Glra3 gene structure, chromosomal localization, and functional characterization of alternative transcripts. *J. Biol. Chem.* 273, 19708–19714.
- Nobles, R. D., Zhang, C., Muller, U., Betz, H., and McCall, M. A. (2012). Selective glycine receptor alpha2 subunit control of crossover inhibition between the on and off retinal pathways. *J. Neurosci.* 32, 3321–3332.
- Oertel, J., Villmann, C., Kettenmann, H., Kirchhoff, F., and Becker, C. M. (2007). A novel glycine receptor beta subunit splice variant predicts an unorthodox transmembrane topology. Assembly into heteromeric receptor complexes. *J. Biol. Chem.* 282, 2798–2807.
- Piechotta, K., Weth, F., Harvey, R. J., and Friauf, E. (2001). Localization of rat glycine receptor alpha1 and alpha2 subunit transcripts in the developing auditory brainstem. *J. Comp. Neurol.* 438, 336–352.
- Pless, S. A., and Lynch, J. W. (2009). Magnitude of a conformational change in the glycine receptor beta1-beta2 loop is correlated with agonist efficacy. *J. Biol. Chem.* 284, 27370–27376.
- Pourcho, R. G. (1996). Neurotransmitters in the retina. *Curr. Eye Res.* 15, 797–803.
- Rajalu, M., Muller, U. C., Caley, A., Harvey, R. J., and Poisbeau, P. (2009). Plasticity of synaptic inhibition in mouse spinal cord lamina II neurons during early postnatal development and after inactivation of the glycine receptor alpha3 subunit gene. *Eur. J. Neurosci.* 30, 2284–2292.
- Rajendra, S., Lynch, J. W., Pierce, K. D., French, C. R., Barry, P. H., and Schofield, P. R. (1994). Startle disease mutations reduce the agonist sensitivity of the human inhibitory glycine receptor. *J. Biol. Chem.* 269, 18739–18742.
- Rampon, C., Luppi, P. H., Fort, P., Peyron, C., and Jouvet, M. (1996). Distribution of glycine-immunoreactive cell bodies and fibers in the rat brain. *Neuroscience* 75, 737–755.
- Ryan, S. G., Buckwalter, M. S., Lynch, J. W., Handford, C. A., Segura, L., Shiang, R., et al. (1994). A missense mutation in the gene encoding the alpha 1 subunit of the inhibitory glycine receptor in the spasmodic mouse. *Nat. Genet.* 7, 131–135.
- Sadtler, S., Laube, B., Lashub, A., Nicke, A., Betz, H., and Schmalzing, G. (2003). A basic cluster determines topology of the cytoplasmic M3-M4 loop of the glycine receptor alpha1 subunit. *J. Biol. Chem.* 278, 16782–16790.
- Samad, T. A., Moore, K. A., Sapirstein, A., Billet, S., Allchorne, A., Poole, S., et al. (2001). Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. *Nature* 410, 471–475.
- Sassoe-Pognetto, M., Wassle, H., and Grunert, U. (1994). Glycinergic synapses in the rod pathway of the rat retina: cone bipolar cells express the alpha 1 subunit of the glycine receptor. *J. Neurosci.* 14, 5131–5146.
- Sato, K., Zhang, J. H., Saika, T., Sato, M., Tada, K., and Tohyama, M. (1991). Localization of glycine receptor alpha 1 subunit mRNA-containing neurons in the rat brain: an analysis using *in situ* hybridization histochemistry. *Neuroscience* 43, 381–395.
- Saul, B., Schmieden, V., Kling, C., Mulhardt, C., Gass, P., Kuhse, J., et al. (1994). Point mutation of glycine receptor alpha 1 subunit in the spasmodic mouse affects agonist responses. *FEBS Lett.* 350, 71–76.
- Scain, A. L., Le Corrionc, H., Allain, A. E., Muller, E., Rigo, J. M., Meyrand, P., et al. (2010). Glycine release from radial cells modulates the spontaneous activity and its propagation during early spinal cord development. *J. Neurosci.* 30, 390–403.
- Shiang, R., Ryan, S. G., Zhu, Y. Z., Hahn, A. F., O'Connell, P., and Wasmuth, J. J. (1993). Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. *Nat. Genet.* 5, 351–358.
- Siembab, V. C., Smith, C. A., Zagoraiou, L., Berrocal, M. C., Mentis, G. Z., and Alvarez, F. J. (2010). Target selection of proprioceptive and motor axon synapses on neonatal V1-derived Ia inhibitory interneurons and Renshaw cells. *J. Comp. Neurol.* 518, 4675–4701.
- Smart, T. G., Hosie, A. M., and Miller, P. S. (2004). Zn²⁺ ions: modulators of excitatory and inhibitory synaptic activity. *Neuroscientist* 10, 432–442.
- Stell, B. M., and Mody, I. (2002). Receptors with different affinities mediate phasic and tonic GABA(A) conductances in hippocampal neurons. *J. Neurosci.* 22, RC223.
- Strausberg, R. L., Feingold, E. A., Grouse, L. H., Derge, J. G., Klausner, R. D., Collins, F. S., et al. (2002). Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. *Proc. Natl. Acad. Sci. U.S.A.* 99, 16899–16903.
- Strutz, N., Villmann, C., Breiting, H. G., Werner, M., Wenthold, R. J., Kizelsstein, P., et al. (2002). Kainate-binding proteins are rendered functional ion channels upon transplantation of two short pore-flanking domains from a kainate receptor. *J. Biol. Chem.* 277, 48035–48042.
- Traka, M., Seburn, K. L., and Popko, B. (2006). Nmf11 is a novel ENU-induced mutation in the mouse glycine receptor alpha 1 subunit. *Mamm. Genome* 17, 950–955.
- Tsai, C. H., Chang, F. C., Su, Y. C., Tsai, F. J., Lu, M. K., Lee, C. C., et al. (2004). Two novel mutations of the glycine receptor gene in a Taiwanese hyperekplexia family. *Neurology* 63, 893–896.

- Unwin, N. (2005). Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution. *J. Mol. Biol.* 346, 967–989.
- Villmann, C., and Becker, C. M. (2007). On the hypes and falls in neuroprotection: targeting the NMDA receptor. *Neuroscientist* 13, 594–615.
- Villmann, C., Hoffmann, J., Werner, M., Kott, S., Strutz-Seebohm, N., Nilsson, T., et al. (2008). Different structural requirements for functional ion pore transplantation suggest different gating mechanisms of NMDA and kainate receptors. *J. Neurochem.* 107, 453–465.
- Villmann, C., Oertel, J., Ma-Hogemeier, Z. L., Hollmann, M., Sprengel, R., Becker, K., et al. (2009a). Functional complementation of Glra1(spdot), a glycine receptor subunit mutant, by independently expressed C-terminal domains. *J. Neurosci.* 29, 2440–2452.
- Villmann, C., Oertel, J., Melzer, N., and Becker, C. M. (2009b). Recessive hyperekplexia mutations of the glycine receptor alpha1 subunit affect cell surface integration and stability. *J. Neurochem.* 111, 837–847.
- von Wegerer, J., Becker, K., Glockenhammer, D., Becker, C. M., Zeilhofer, H. U., and Swandulla, D. (2003). Spinal inhibitory synaptic transmission in the glycine receptor mouse mutant spastic. *Neurosci. Lett.* 345, 45–48.
- Waldvogel, H. J., Baer, K., Allen, K. L., Rees, M. I., and Faull, R. L. (2007). Glycine receptors in the striatum, globus pallidus, and substantia nigra of the human brain: an immunohistochemical study. *J. Comp. Neurol.* 502, 1012–1029.
- Weiss, J., O'Sullivan, G. A., Heinze, L., Chen, H. X., Betz, H., and Wassle, H. (2008). Glycinergic input of small-field amacrine cells in the retinas of wildtype and glycine receptor deficient mice. *Mol. Cell. Neurosci.* 37, 40–55.
- White, W. F., and Heller, A. H. (1982). Glycine receptor alteration in the mutant mouse spastic. *Nature* 298, 655–657.
- Williams, K. L., Ferko, A. P., Barbieri, E. J., and DiGregorio, G. J. (1995). Glycine enhances the central depressant properties of ethanol in mice. *Pharmacol. Biochem. Behav.* 50, 199–205.
- Young, T. L., and Cepko, C. L. (2004). A role for ligand-gated ion channels in rod photoreceptor development. *Neuron* 41, 867–879.
- Young-Pearse, T. L., Ivic, L., Kriegstein, A. R., and Cepko, C. L. (2006). Characterization of mice with targeted deletion of glycine receptor alpha 2. *Mol. Cell. Biol.* 26, 5728–5734.
- Ziv, I., Blackburn, N., Rang, M., and Koreska, J. (1984). Muscle growth in normal and spastic mice. *Dev. Med. Child Neurol.* 26, 94–99.
- Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 07 August 2012; accepted: 11 October 2012; published online: 31 October 2012.

Citation: Schaefer N, Vogel N and Villmann C (2012) Glycine receptor mutants of the mouse: what are possible routes of inhibitory compensation? *Front. Mol. Neurosci.* 5:98. doi: 10.3389/fnmol.2012.00098

Copyright © 2012 Schaefer, Vogel and Villmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.